<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257620</url>
  </required_header>
  <id_info>
    <org_study_id>Celiac</org_study_id>
    <nct_id>NCT01257620</nct_id>
  </id_info>
  <brief_title>Clinical Trial on the Effects of Bifidobacterium Infantis in Active Celiac Disease</brief_title>
  <acronym>Celiac</acronym>
  <official_title>Exploratory, Randomized, Double-blind, Placebo-Controlled Study on the Effects of Bifidobacterium Infantis in Active Celiac Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bai, Julio M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The National Institute of Probiotics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bai, Julio M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This exploratory study has been designed to determine the effect of the probiotic
      Bifidobacterium infantis vs. placebo orally administered over a period of 3 weeks on clinical
      features, Quality of Life parameters (QoL), intestinal permeability and inflammatory markers
      of patients having positive serological evidences of Celiac Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: This exploratory study has been designed to determine the effect of the probiotic
      Bifidobacterium infantis vs. placebo orally administered over a period of 3 weeks on clinical
      features, Quality of Life parameters (QoL), intestinal permeability and inflammatory markers
      of patients having serological evidences of CD (positive serological markers). The testing
      period will be approximately three weeks between the results of serological testing and
      before the intestinal biopsy procedure during which time subjects are consuming a
      gluten-containing diet.

      Study Design: A 3-weeks duration, placebo-controlled, double-blind, randomized study plan in
      ambulatory (non-hospitalized outpatients) patients, with 2 parallel groups. Treatment arms
      will be as follows:

      A). Placebo 2 capsules 3 times daily (morning, evening and night).

      B). Probiotics (Bifidobacterium infantis) 2 capsules 3 times per day (morning, evening and
      night).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intestinal permeability changes</measure>
    <time_frame>21 days</time_frame>
    <description>Subjects will come to the laboratory after an overnight fast, ingest the sugar probes, and collect all urine passed over the ensuing 24 hours into a pre-weighed container with 5 ml of 10% thymol in isopropanol. Urine will be vigorously mixed, total volume recorded, and aliquots rapidly frozen for subsequent transport and analysis. To evaluate intestinal permeability, subjects will ingest a solution containing: 5 g lactulose (Technilab, Montreal, Quebec, Canada), and 2 g mannitol (Sigma, St Louis, Missouri, USA) in 450 ml of water (osmolality approximately 1800 mOsmol/l).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the cytokine profile.</measure>
    <time_frame>21 days</time_frame>
    <description>Mononuclear cells obtained from blood will be isolated by Ficoll-Hypaque density centrifugation and resuspended in complete media/Dulbecco's modified Eagle medium. These mononuclear cells will be termed peripheral blood mononuclear cells (PBMCs). PBMCs will be incubated, nonstimulated, for 72 hours at 37Â°C in a 5% CO2 humidified atmosphere. Nonstimulated PBMC cytokine reflects the cytokine milieu from wich the PBMCs were originally isolated. Interleukin(IL)-10 and IL-12p40 cytokine levels will be measured using enzyme-linked immunosorbent assays.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Life Start Two</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Bifidobacterium infantis, 2 capsules (2.0E+9 CFU/capsule) 3 times/day for a total of 1.2E+10 CFU/day for 21 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Probiotic</arm_group_label>
    <other_name>Natren Inc.</other_name>
    <other_name>Life Start Two</other_name>
    <other_name>Bifidobacterium infantis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signing the Informed consent.

          -  Men or women, 18-75 years old.

          -  BMI between 18.5 and 35.

          -  Patients shall have a positive CD-related serology (combined positivity of DGP/tTG
             Screen plus IgA anti-tTG and or IgA a-DGP tests).

          -  Patients will abstain from taking medications prohibited by the study from the 7 days
             prior the enrolment to the end of the trial: NSAIDs, aspirin, lactulose, probiotics
             and prebiotics in any form of administration (eg. Yogurts or other dairy products)..

          -  Alcohol consumption is prohibited during the same period.

          -  Patients should commit to attend on scheduled days, in accordance with the study
             calendar.

          -  To be interested in participating the trial

        Exclusion Criteria:

          -  Patients with refractory CD or severe complications thereof, enteropathy-associated
             T-cell Lymphoma (EATL), ulcerative jejunitis, perforation, severe osteoporosis,
             malnutrition, among others.

          -  Individuals with symptoms suggestive of lymphoma or any other serious CD complication
             taking special care in recently-diagnosed patients, 50 years old or older, in whom
             EATL must be ruled out by standard methods.

          -  Individuals with other active chronic GI pathologies like Crohn's disease, ulcerative
             colitis and irritable bowel syndrome, microscopic colitis, and lactose intolerance.

          -  Patients with Type 1 or Type 2 diabetes or other autoimmune diseases, such as
             autoimmune hepatitis and primary biliary cirrhosis.

          -  Individuals with co-morbidities whose participation, in the investigator's judgment,
             would be inadvisable; for instance, unstable clinical conditions such as chronic
             obstructive pulmonary disease, angina pectoris, severe cardio-respiratory conditions,
             etc.

          -  Individuals with symptomatic neurological or psychiatric conditions that could
             potentially interfere with the study.

          -  Individuals with a clinical severity requiring immediate treatment at the
             consideration of the investigator.

          -  Patients with hemoglobin levels less than 8.5 g/dL or who had donated blood in the
             last 56 days or donated a unit of plasma in the last 7 days.

          -  Patients with a history of alcohol or drug abuse in the prior 2 years.

          -  Individuals taking &quot;prohibited&quot; medications in relation to the study (see point 6,
             previous section).

          -  Individuals with a history of neoplasia.

          -  Individuals participating in another clinical study that either involves medications
             or concluded during the last 30 days.

          -  Individuals previously exposed to Bifidobacteria species.

          -  Subjects not willing to maintain a gluten-containing diet during the 3-weeks period of
             the trial

          -  Pregnant women.

          -  Allergies to goat milk; no recent or planned dietary changes, esp. regarding gluten
             intake.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio C Bai, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Dr. C. Bonorino Udaondo Gastroenterology Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edgardo Smecuol, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. C. Bonorino Udaondo Gastroenterology Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. C. Bonorino Udanondo Gastroenterology Hospital</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Sander GR, Cummins AG, Henshall T, Powell BC. Rapid disruption of intestinal barrier function by gliadin involves altered expression of apical junctional proteins. FEBS Lett. 2005 Aug 29;579(21):4851-5.</citation>
    <PMID>16099460</PMID>
  </reference>
  <reference>
    <citation>Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, Rispo A, Griffin M, Issekutz T, Quaratino S, Londei M. Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology. 2005 Nov;129(5):1400-13.</citation>
    <PMID>16285941</PMID>
  </reference>
  <reference>
    <citation>Barone MV, Gimigliano A, Castoria G, Paolella G, Maurano F, Paparo F, Maglio M, Mineo A, Miele E, Nanayakkara M, Troncone R, Auricchio S. Growth factor-like activity of gliadin, an alimentary protein: implications for coeliac disease. Gut. 2007 Apr;56(4):480-8. Epub 2006 Aug 4.</citation>
    <PMID>16891357</PMID>
  </reference>
  <reference>
    <citation>RollÃ¡n G, De Angelis M, Gobbetti M, de Valdez GF. Proteolytic activity and reduction of gliadin-like fractions by sourdough lactobacilli. J Appl Microbiol. 2005;99(6):1495-502.</citation>
    <PMID>16313422</PMID>
  </reference>
  <reference>
    <citation>Di Cagno R, De Angelis M, Lavermicocca P, De Vincenzi M, Giovannini C, Faccia M, Gobbetti M. Proteolysis by sourdough lactic acid bacteria: effects on wheat flour protein fractions and gliadin peptides involved in human cereal intolerance. Appl Environ Microbiol. 2002 Feb;68(2):623-33.</citation>
    <PMID>11823200</PMID>
  </reference>
  <reference>
    <citation>Di Cagno R, De Angelis M, Auricchio S, Greco L, Clarke C, De Vincenzi M, Giovannini C, D'Archivio M, Landolfo F, Parrilli G, Minervini F, Arendt E, Gobbetti M. Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in celiac sprue patients. Appl Environ Microbiol. 2004 Feb;70(2):1088-96.</citation>
    <PMID>14766592</PMID>
  </reference>
  <reference>
    <citation>Gerez CL, RollÃ¡n GC, de Valdez GF. Gluten breakdown by lactobacilli and pediococci strains isolated from sourdough. Lett Appl Microbiol. 2006 May;42(5):459-64.</citation>
    <PMID>16620203</PMID>
  </reference>
  <reference>
    <citation>Rizzello CG, De Angelis M, Di Cagno R, Camarca A, Silano M, Losito I, De Vincenzi M, De Bari MD, Palmisano F, Maurano F, Gianfrani C, Gobbetti M. Highly efficient gluten degradation by lactobacilli and fungal proteases during food processing: new perspectives for celiac disease. Appl Environ Microbiol. 2007 Jul;73(14):4499-507. Epub 2007 May 18.</citation>
    <PMID>17513580</PMID>
  </reference>
  <reference>
    <citation>Lindfors K, Blomqvist T, Juuti-Uusitalo K, Stenman S, VenÃ¤lÃ¤inen J, MÃ¤ki M, Kaukinen K. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol. 2008 Jun;152(3):552-8. doi: 10.1111/j.1365-2249.2008.03635.x. Epub 2008 Apr 16.</citation>
    <PMID>18422736</PMID>
  </reference>
  <reference>
    <citation>De Palma G, Nadal I, Medina M, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol. 2010 Feb 24;10:63. doi: 10.1186/1471-2180-10-63.</citation>
    <PMID>20181275</PMID>
  </reference>
  <reference>
    <citation>De Palma G, Cinova J, Stepankova R, Tuckova L, Sanz Y. Pivotal Advance: Bifidobacteria and Gram-negative bacteria differentially influence immune responses in the proinflammatory milieu of celiac disease. J Leukoc Biol. 2010 May;87(5):765-78. doi: 10.1189/jlb.0709471. Epub 2009 Dec 10.</citation>
    <PMID>20007908</PMID>
  </reference>
  <reference>
    <citation>Di Cagno R, Rizzello CG, Gagliardi F, Ricciuti P, Ndagijimana M, Francavilla R, Guerzoni ME, Crecchio C, Gobbetti M, De Angelis M. Different fecal microbiotas and volatile organic compounds in treated and untreated children with celiac disease. Appl Environ Microbiol. 2009 Jun;75(12):3963-71. doi: 10.1128/AEM.02793-08. Epub 2009 Apr 17.</citation>
    <PMID>19376912</PMID>
  </reference>
  <reference>
    <citation>Collado MC, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Imbalances in faecal and duodenal Bifidobacterium species composition in active and non-active coeliac disease. BMC Microbiol. 2008 Dec 22;8:232. doi: 10.1186/1471-2180-8-232.</citation>
    <PMID>19102766</PMID>
  </reference>
  <reference>
    <citation>Medina M, De Palma G, Ribes-Koninckx C, Calabuig M, Sanz Y. Bifidobacterium strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients. J Inflamm (Lond). 2008 Nov 3;5:19. doi: 10.1186/1476-9255-5-19.</citation>
    <PMID>18980693</PMID>
  </reference>
  <reference>
    <citation>Nadal I, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Imbalance in the composition of the duodenal microbiota of children with coeliac disease. J Med Microbiol. 2007 Dec;56(Pt 12):1669-74. Erratum in: J Med Microbiol. 2008 Mar;57(Pt 3):401. Donant, Esther [corrected to Donat, Ester].</citation>
    <PMID>18033837</PMID>
  </reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2010</study_first_posted>
  <last_update_submitted>February 10, 2012</last_update_submitted>
  <last_update_submitted_qc>February 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. C. Bonorino Udaondo Gastroenterology Hospital</investigator_affiliation>
    <investigator_full_name>Bai, Julio M.D.</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Coeliac Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

